| Literature DB >> 35361107 |
Kathrin Weidner1,2, Michael Behnes3,4, Tobias Schupp1,2, Jorge Hoppner5, Ibrahim El-Battrawy1,2, Uzair Ansari1,2, Ahmad Saleh1,2, Gabriel Taton1,2, Linda Reiser1,2, Armin Bollow1,2, Thomas Reichelt1,2, Dominik Ellguth1,2, Niko Engelke1,2, Thomas Bertsch6, Dirk Große Meininghaus7, Ursula Hoffmann1,2, Ibrahim Akin1,2.
Abstract
BACKGROUND: This study evaluates cardiac diseases and prognosis in young adults and adults presenting with ventricular tachyarrhythmias (VTA).Entities:
Keywords: Age; Cardiac-related disease; Cardiovascular risk factors; Coronary artery disease; Long-term mortality; Ventricular tachyarrhythmia; Young adults
Mesh:
Year: 2022 PMID: 35361107 PMCID: PMC8973880 DOI: 10.1186/s12872-022-02552-6
Source DB: PubMed Journal: BMC Cardiovasc Disord ISSN: 1471-2261 Impact factor: 2.298
Clinical characteristics
| Characteristic | Young adults | Adults | |
|---|---|---|---|
| Males, n (%) | 53 (58) | 118 (71) | |
| Ventricular tachyarrhythmias, n (%) | |||
| Ventricular tachycardia | 54 (59) | 79 (47) | |
| Non-sustained VT | 27 (50) | 47 (60) | 0.279 |
| Sustained VT | 27 (50) | 32 (40) | |
| Ventricular fibrillation | 38 (41) | 88 (53) | 0.079 |
| Cardiopulmonary resuscitation, n (%) | 29 (31) | 76 (45) | |
| In-hospital | 15 (16) | 57 (34) | |
| Out-of-hospital | 14 (15) | 19 (11) | |
| Cardiovascular risk factors, n (%) | |||
| Arterial hypertension | 7 (8) | 44 (26) | |
| Diabetes mellitus | 3 (3) | 13 (8) | 0.148 |
| Hyperlipidemia | 6 (7) | 31 (19) | |
| Smoking | 20 (22) | 57 (34) | |
| Cardiac family history | 14 (15) | 34 (20) | 0.308 |
| Prior medical history, n (%) | |||
| Prior heart failure | 4 (4) | 16 (10) | 0.131 |
| Atrial fibrillation | 6 (7) | 19 (11) | 0.205 |
| Prior stroke | 0 (0) | 2 (1) | 0.540 |
| COPD | 0 (0) | 1 (0.6) | 1.000 |
| Chronic kidney disease | 16 (17) | 54 (33) | |
| Laboratory data, mean ± SEM | |||
| Hemoglobin [g/dl] | 13.7 ± 2.2 | 14.1 ± 1.7 | 0.093 |
| Potassium [mg/dl] | 4.1 ± 0.1 | 4.3 ± 0.1 | 0.603 |
| Creatinine [mg/dl] | 1.0 ± 0.0 | 1.7 ± 0.4 | 0.093 |
| Medication at discharge, n (%) | |||
| Beta blocker | 48 (58) | 89 (65) | 0.290 |
| ACE inhibitor/ARB | 20 (24) | 63 (46) | |
| Aldosterone antagonist | 4 (5) | 10 (7) | 0.465 |
| Digitalis | 1 (1) | 7 (5) | 0.134 |
| Amiodarone | 4 (4) | 6 (4) | 0.879 |
| Statin | 9 (11) | 52 (38) | |
| Patients discharged alive, n (%) | 83 (90) | 137 (82) | 0.078 |
| Hospitalization time in days, median (IQR) | |||
| Total hospitalization time | 6 (1–52) | 8 (1–55) | 0.410 |
| ICU time | 1 (0–28) | 2 (0–31) | 0.523 |
| Follow-up time in days, mean; median (range) | 2217; 2338 (0–4608) | 2039; 1931 (9–5095) | 0.262 |
Bold type indicates statistical significance p < 0.05
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; IQR, interquartile range; VT, Ventricular tachycardia
Cardiac comorbidities at index hospitalization
| Characteristic | Young adults | Adults | |
|---|---|---|---|
| Left ventricular function, n (%) | |||
| LVEF > 55% | 33 (36) | 57 (34) | 0.188 |
| LVEF 45–55% | 14 (15) | 17 (10) | |
| LVEF 35–44% | 11 (12) | 22 (13) | |
| LVEF < 35% | 5 (5) | 22 (13) | |
| Not documented | 29 (32) | 49 (29) | 0.714 |
| Primary cardiomyopathies, n (%) | 11 (12) | 16 (10) | |
| Dilated cardiomyopathy | 5 (5) | 11 (7) | 0.712 |
| Hypertrophic cardiomyopathy | 0 (0) | 5 (3) | 0.200 |
| Arrhythmogenic right ventricular dysplasia | 6 (7) | 0 (0) | |
| Noncompaction cardiomyopathy | 0 (0) | 0 (0) | – |
| Restrictive cardiomyopathy | 0 (0) | 0 (0) | – |
| Channelopathies, n (%) | 17 (18) | 19 (12) | |
| Brugada syndrome | 13 (14) | 16 (10) | 0.245 |
| Short QT syndrome | 0 (0) | 0 (0) | – |
| Long QT syndrome | 4 (4) | 3 (2) | 0.168 |
| Other causes, n (%) | |||
| Myocarditis | 7 (8) | 4 (2) | |
| Takotsubo cardiomyopathy | 0 (0) | 0 (0) | |
| High degree AV-block | 1 (1) | 1 (1) | 0.668 |
| Intoxication | 6 (7) | 4 (2) | 0.064 |
| Hyperkalemia | 4 (4) | 17 (10) | 0.099 |
| Hypokalemia | 18 (20) | 17 (10) | |
| Coronary artery disease, n (%) | |||
| Prior CAD | 4 (4) | 20 (12) | |
| Prior AMI | 1 (1) | 16 (10) | |
| AMI at index | 10 (11) | 46 (28) | |
| STEMI | 4 (4) | 20 (12) | |
| NSTEMI | 6 (7) | 26 (16) | |
| Coronary angiography at index | 26 (28) | 96 (58) | |
| No evidence of CAD | 16 (62) | 45 (47) | 0.089 |
| Evidence of CAD | 10 (38) | 51 (53) | 0.184 |
| 1-vessel | 10 (100) | 31 (61) | |
| 2-vessel | 0 (0) | 15 (29) | |
| 3-vessel | 0 (0) | 5 (10) | |
| Intracoronary thrombus | 5 (19) | 13 (13) | 0.455 |
| CABG | 0 (0) | 2 (2) | 0.458 |
| CTO | 0 (0) | 9 (9) | 0.105 |
| PCI | 10 (100) | 43 (84) | 0.564 |
| RCA | 5 (50) | 14 (30) | 0.384 |
| LMT | 0 (0) | 0 (0) | – |
| LAD | 5 (50) | 23 (50) | 1.000 |
| RIM | 0 (0) | 0 (0) | – |
| RCX | 0 (0) | 9 (20) | |
| Sent to CABG | 0 (0) | 0 (0) | – |
| Electrophysiological examination, n (%) | 45 (49) | 68 (41) | 0.203 |
| VT ablation | 14 (31) | 18 (26) | 0.175 |
| Presence of ICD at discharge, n (%) | 35 (38) | 63 (38) | 0.959 |
| Type of ICD, n (%) | |||
| ICD | 31 (89) | 58 (92) | 0.788 |
| CRT-D | 0 (0) | 1 (2) | |
| s-ICD | 4 (11) | 4 (6) | |
| ICD programming, BPM, median (IQR) | |||
| VT detection threshold | 191 (176–205) | 171 (167–176) | 0.735 |
| VF detection threshold | 231 (231–240) | 176 (167–176) | |
Bold type indicates statistical significance p < 0.05
AV-block, atrioventricular block; BPM, beats per minute; CABG, Coronary artery bypass graft; CAD, coronary artery disease; CTO, coronary chronic total occlusion; ICD, implantable cardioverter-defibrillator. LAD, left anterior descending artery; LMT, left main trunk, LVEF, left ventricular ejection fraction; NSTEMI, non–ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; RCA, right coronary artery; RCX, ramus circumflexus; RIM, ramus intermedius; STEMI, ST-Segment elevation myocardial infarction; VF, Ventricular fibrillation; VT, Ventricular tachycardia
Fig. 1Bar diagram depicting coronary angiography rates, relevant CAD, and need for PCI according to age
Fig. 2Cardiac diseases underlying VTA in young adults (left chart) and adults (right chart)
Fig. 3Cardiac diseases in patients who received CPR due to VTA at index hospitalization
Primary and secondary endpoints
| Characteristic | Young adults 0–34 years old (n = 92; 36%) | Adults 35–45 years old (n = 167; 64%) | |
|---|---|---|---|
| Primary endpoint, n (%) | |||
| All-cause mortality at 2.5 years | 11 (12) | 36 (21) | 0.058 |
| Secondary endpoints, n (%) | |||
| Cardiac death at 24 h | 8 (9) | 18 (11) | 0.593 |
| All-cause mortality at index hospitalization | 9 (10) | 30 (18) | 0.078 |
| All-cause mortality after index hospitalization | 4 (4) | 15 (9) | 0.171 |
| Composite endpoint at 2.5 years (Cardiac death at 24 h, recurrent ventricular tachyarrhythmias, appropriate ICD therapies) | 21 (23) | 33 (20) | 0.561 |
ICD, implantable cardioverter-defibrillator
Fig. 4Kaplan–Meier analysis for the primary endpoint of all-cause mortality at 2.5 years and the composite arrhythmic endpoint in patients with ventricular fibrillation and sustained VT (panel I and III) and in patients with non-sustained VT (panel II and IV)
Multivariate Cox regression models
| Variables | All-cause mortality at 2.5 years | |||||
|---|---|---|---|---|---|---|
| Young adults 20–34 years old 20–34 years old (n = 92; 36%) | Adults 35–45 years old 35–45 years old (n = 167; 64%) | |||||
| HR | 95% CI | HR | 95% CI | |||
| Males | 0.095 | 0.007–1.240 | 0.273 | 1.135 | 0.299–4.310 | 0.852 |
| Chronic kidney disease | 1.064 | 0.090–1.064 | 0.961 | 2.492 | 0.822–7.553 | 0.106 |
| LVEF < 35% | 33.590 | 2.395–471.404 | 2.296 | 0.822–7.553 | 0.164 | |
| AMI | 2.073 | 0.149–28.910 | 0.588 | 1.053 | 0.364–3.047 | 0.924 |
| Atrial fibrillation | 11.090 | 0.618–199.219 | 0.102 | 1.469 | 0.364–3.047 | 0.459 |
| Ventricular fibrillation | 3.840 | 0.322–44.354 | 0.281 | 2.975 | 0.904–9.796 | 0.073 |
Bold type indicates statistical significance p < 0.05
AMI, acute myocardial infarction; CI, confidence interval; HR, Hazard ratio; LVEF, left ventricular ejection fraction